文献速递眼底病与葡萄膜炎

AAV8介导视网膜PD-L1基因转导恢复局部免疫耐受减轻实验性自身免疫性葡萄膜炎

AAV8-Mediated Retinal PD-L1 Gene Transfer Attenuates Experimental Autoimmune Uveitis by Restoring Local Immune Tolerance.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2026-01-01

该研究在EAU大鼠模型中于诱导前7天视网膜下注射AAV8/PD-L1,结果显示PD-L1组前房炎症评分降低(P < 0.05)、视网膜T细胞和白细胞浸润减少(P < 0.05)、IL-17表达下调,正常眼注射后未见结构或功能异常。结论认为AAV8介导的PD-L1过表达通过恢复视网膜免疫耐受抑制EAU进展,为眼部自身免疫病局部免疫调节的基因治疗提供策略。

要点

  • EAU诱导前7天视网膜下注射AAV8/PD-L1可增强视网膜PD-L1表达并减轻炎症。
  • PD-L1组前房炎症评分和视网膜T细胞/白细胞浸润均显著降低(P < 0.05)。
  • 正常大鼠眼注射AAV8/PD-L1后未观察到结构或功能异常。

核心结论

  • AAV8介导的PD-L1过表达通过恢复视网膜免疫耐受、减轻炎症并保护视觉功能来抑制EAU进展。
  • 该策略为眼部自身免疫病的局部免疫调节基因治疗提供了有前景的方向。

研究设计与样本

  • 在EAU诱导前7天对Lewis大鼠行视网膜下注射AAV8/PD-L1,以IRBP加完全弗氏佐剂免疫诱导EAU。
  • 于免疫后第8、10、12、14天记录临床炎症评分,第12天行ERG和OCT评估,第14天取眼行组织病理、免疫荧光和流式细胞分析。
  • 另以正常大鼠注射AAV8/PD-L1评估视网膜安全性。

主要发现

  • AAV8/PD-L1显著增强视网膜PD-L1表达,与未治疗EAU大鼠相比显著减轻眼内炎症和组织损伤。
  • PD-L1组前房炎症评分降低(P < 0.05)。
  • PD-L1组视网膜T细胞和白细胞浸润减少(P < 0.05)。
  • PD-L1组IL-17表达下调。
  • 正常眼注射AAV8/PD-L1后未观察到结构或功能异常。

临床怎么用

  • 提示视网膜下AAV8递送PD-L1可能作为局部免疫调节手段用于眼部自身免疫性疾病的实验性治疗。
  • 正常大鼠眼的安全性观察支持进一步评估该基因治疗策略的视网膜安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the therapeutic potential of the programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) immune checkpoint pathway in experimental autoimmune uveitis (EAU) and to elucidate its role in regulating the retinal immune microenvironment. METHODS: Seven days before EAU induction, Lewis rats received subretinal injections of adeno-associated virus serotype 8 (AAV8)/PD-L1. EAU was induced by immunization with interphotoreceptor retinoid-binding protein (IRBP) in complete Freund's adjuvant. Clinical inflammation scores were recorded on days 8, 10, 12, and 14 post-immunizations. Retinal function was evaluated by electroretinography (ERG) on day 12, and structural changes were assessed by optical coherence tomography (OCT). On day 14, eyes were harvested for histopathological examination, immunofluorescence, and flow cytometric analyses of leukocyte infiltration and cytokine expression. Normal rats injected with AAV8/PD-L1 were examined to assess retinal safety. RESULTS: AAV8/PD-L1 markedly enhanced PD-L1 expression in the retina, resulting in significantly reduced intraocular inflammation and tissue damage compared with untreated EAU rats. The PD-L1 group showed lower anterior chamber inflammation scores (P < 0.05), decreased retinal T-cell and leukocyte infiltration (P < 0.05), and downregulated expression of IL-17. No structural or functional abnormalities were observed in normal eyes treated with AAV8/PD-L1. CONCLUSIONS: AAV8-mediated PD-L1 overexpression suppresses EAU progression by restoring retinal immune tolerance, attenuating inflammation, and preserving visual function. This approach offers a promising gene therapy strategy for local immune modulation in ocular autoimmune diseases.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Lai Q, Jin Y, Ding J, et al. AAV8-Mediated Retinal PD-L1 Gene Transfer Attenuates Experimental Autoimmune Uveitis by Restoring Local Immune Tolerance. Invest Ophthalmol Vis Sci. 2026. PMID: 42405669. doi:10.1167/iovs.67.8.17

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。